Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

The Alpha Emitter Astatine-211 Targeted to CD38 can Eradicate Multiple Myeloma in a Disseminated Disease Model.

O'Steen S, Comstock ML, Orozco JJ, Hamlin DK, Wilbur DSS, Jones JC, Kenoyer A, Nartea ME, Lin Y, Miller BW, Gooley TA, Tuazon SA, Till BG, Gopal AK, Sandmaier BM, Press OW, Green DJ.

Blood. 2019 Aug 8. pii: blood.2019001250. doi: 10.1182/blood.2019001250. [Epub ahead of print]

PMID:
31395601
2.

cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies.

Li Y, Hamlin DK, Chyan MK, Wong R, Dorman EF, Emery RC, Woodle DR, Manger RL, Nartea M, Kenoyer AL, Orozco JJ, Green DJ, Press OW, Storb R, Sandmaier BM, Wilbur DS.

PLoS One. 2018 Oct 18;13(10):e0205135. doi: 10.1371/journal.pone.0205135. eCollection 2018.

3.

Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.

Lee SY, Olsen P, Lee DH, Kenoyer AL, Budde LE, O'Steen S, Green DJ, Heimfeld S, Jensen MC, Riddell SR, Press OW, Till BG.

J Immunother. 2018 Jan;41(1):19-31. doi: 10.1097/CJI.0000000000000199.

4.

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

Green DJ, O'Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK, Wilbur DS, Fisher DR, Nartea M, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, Orcutt KD, Wittrup KD, Press OW.

Blood. 2018 Feb 8;131(6):611-620. doi: 10.1182/blood-2017-09-807610. Epub 2017 Nov 20.

5.

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

O'Steen S, Green DJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y, Wilbur DS, Hamlin DK, Fisher DR, Hylarides MD, Gooley TA, Waltman A, Till BG, Press OW.

Cancer Res. 2017 Jul 15;77(14):3885-3893. doi: 10.1158/0008-5472.CAN-17-0082. Epub 2017 May 31.

6.

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SH, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, O'Steen S, Orcutt KD, Wilbur DS, Wittrup KD, Press OW.

Cancer Res. 2016 Nov 15;76(22):6669-6679. doi: 10.1158/0008-5472.CAN-16-0571. Epub 2016 Sep 2.

7.

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Orozco JJ, Kenoyer A, Balkin ER, Gooley TA, Hamlin DK, Wilbur DS, Hylarides MD, Frost SH, Mawad R, O'Donnell P, Sandmaier BM, Fuchs EJ, Luznik L, Green DJ, Gopal AK, Press OW, Pagel JM.

Blood. 2016 Jan 21;127(3):352-9. doi: 10.1182/blood-2014-12-617019. Epub 2015 Nov 17.

8.

α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation.

Frost SH, Miller BW, Bäck TA, Santos EB, Hamlin DK, Knoblaugh SE, Frayo SL, Kenoyer AL, Storb R, Press OW, Wilbur DS, Pagel JM, Sandmaier BM.

J Nucl Med. 2015 Nov;56(11):1766-73. doi: 10.2967/jnumed.115.162388. Epub 2015 Sep 3.

9.

Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.

Miller BW, Frost SH, Frayo SL, Kenoyer AL, Santos E, Jones JC, Green DJ, Hamlin DK, Wilbur DS, Fisher DR, Orozco JJ, Press OW, Pagel JM, Sandmaier BM.

Med Phys. 2015 Jul;42(7):4094-105. doi: 10.1118/1.4921997.

10.

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur DS, Balkan ER, Lin Y, Miller BW, Frost SH, Gopal AK, Orozco JJ, Gooley TA, Laird KL, Till BG, Bäck T, Sandmaier BM, Pagel JM, Press OW.

Blood. 2015 Mar 26;125(13):2111-9. doi: 10.1182/blood-2014-11-612770. Epub 2015 Jan 27.

11.

Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.

Orozco JJ, Balkin ER, Gooley TA, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Hylarides MD, Shadman M, Green DJ, Gopal AK, Press OW, Pagel JM.

PLoS One. 2014 Dec 2;9(12):e113601. doi: 10.1371/journal.pone.0113601. eCollection 2014.

12.

In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.

Balkin ER, Kenoyer A, Orozco JJ, Hernandez A, Shadman M, Fisher DR, Green DJ, Hylarides MD, Press OW, Wilbur DS, Pagel JM.

Cancer Res. 2014 Oct 15;74(20):5846-54. doi: 10.1158/0008-5472.CAN-14-0764. Epub 2014 Sep 26.

13.

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

Green DJ, Orgun NN, Jones JC, Hylarides MD, Pagel JM, Hamlin DK, Wilbur DS, Lin Y, Fisher DR, Kenoyer AL, Frayo SL, Gopal AK, Orozco JJ, Gooley TA, Wood BL, Bensinger WI, Press OW.

Cancer Res. 2014 Feb 15;74(4):1179-89. doi: 10.1158/0008-5472.CAN-13-1589. Epub 2013 Dec 26.

14.

Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

Orozco JJ, Bäck T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, Fisher DR, Frayo SL, Hylarides MD, Green DJ, Gopal AK, Press OW, Pagel JM.

Blood. 2013 May 2;121(18):3759-67. doi: 10.1182/blood-2012-11-467035. Epub 2013 Mar 7.

15.

Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.

Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur DS, Stayton PS, Orgun N, Hylarides M, Buchegger F, Kenoyer AL, Axtman A, Gopal AK, Green DJ, Pagel JM, Press OW.

Clin Cancer Res. 2011 Dec 1;17(23):7373-82. doi: 10.1158/1078-0432.CCR-11-1204. Epub 2011 Oct 5.

16.

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.

Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW.

Blood. 2011 Jul 21;118(3):703-11. doi: 10.1182/blood-2011-04-347039. Epub 2011 May 25.

17.

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW.

Blood. 2010 Nov 18;116(20):4231-9. doi: 10.1182/blood-2010-05-282327. Epub 2010 Aug 11.

18.

Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.

Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Hamlin DK, Wilbur DS, Fisher DR, Rajendran JG, Gopal AK, Park SI, Press OW.

Blood. 2009 Aug 6;114(6):1226-35. doi: 10.1182/blood-2009-03-210344. Epub 2009 Jun 10.

19.

Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.

Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, Kenoyer AL, Pagel JM, Press OW, Storb R, Sandmaier BM.

Cancer Res. 2009 Mar 15;69(6):2408-15. doi: 10.1158/0008-5472.CAN-08-4363. Epub 2009 Feb 24.

20.

Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.

Pagel JM, Matthews DC, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Gopal AK, Lin Y, Saganic L, Appelbaum FR, Press OW.

Cancer Res. 2009 Jan 1;69(1):185-92. doi: 10.1158/0008-5472.CAN-08-2513.

21.
22.

Supplemental Content

Loading ...
Support Center